Schedule 13G ownership disclosure

Prelude Therapeutics, Inc.

Security class unavailable · CUSIP: 74065P101

Event date: 2022-12-30

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
2,507,992
Percent of class
5.2400%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000861177-23-000003
Form type
SC 13G
Filer
Prelude Therapeutics Inc
CIK
CIK 1678660
Filed
Feb 13, 2023
Reporting period
Dec 30, 2022
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub